Vitamin B3 Shows Promise for 30% of World With Fatty Liver

A vitamin sitting on pharmacy shelves might hold the answer to a disease affecting 800 million people around the world.

Researchers at South Korea's UNIST have identified why fatty liver disease develops and discovered that vitamin B3 can effectively stop it. The finding could transform treatment for a condition that has lacked safe, targeted therapies for decades.

The research team, led by Professor Jang Hyun Choi, pinpointed a tiny molecule called microRNA-93 as the culprit behind fatty liver disease. When levels of this molecule spike in liver cells, it triggers fat buildup, inflammation, and scarring by suppressing a protective gene called SIRT1.

The scientists tested their theory by using gene editing to block microRNA-93 production in mice. The animals showed dramatically less liver fat, better insulin sensitivity, and improved overall liver function.

Then came the surprising discovery. The team screened 150 FDA-approved medications to find which ones could lower microRNA-93 levels, and niacin (vitamin B3) emerged as the most effective option.

Mice treated with vitamin B3 showed sharp drops in the harmful molecule while their protective SIRT1 activity increased. The treatment helped restore normal fat processing in the liver and improved overall metabolic health.

The Ripple Effect

This discovery matters beyond the lab. Fatty liver disease affects roughly 30% of people globally and can progress to chronic inflammation, cirrhosis, and even liver cancer. Until now, patients have had few treatment options beyond lifestyle changes.

Vitamin B3 is already approved, widely available, and has a long safety record for treating high cholesterol. That means it could reach patients much faster than a newly developed drug, which typically takes years of additional testing.

The international team included researchers from Pusan National University and Ulsan University Hospital. Their work was supported by the National Research Foundation of Korea and published in the journal Metabolism: Clinical and Experimental.

Professor Choi's team emphasized that niacin could be particularly valuable as part of combination therapies targeting multiple pathways in fatty liver disease. The vitamin's established safety profile makes it an ideal candidate for pairing with other treatments.

While more research is needed to confirm the results in human patients, the discovery opens a clear path forward for clinical trials.

For the 2.4 billion people worldwide living with or at risk for fatty liver disease, a solution may already be waiting in the vitamin aisle.